Jun 08, 2023 / 03:00PM GMT
Roger Song - Jefferies LLC - Analyst
All right. Welcome, everyone, day two 2023 Jefferies healthcare conference. My name is Roger Song, one of the senior biotech analysts here. Next presenting company is Aadi, and we have the CFO and Interim CEO, Scott. Welcome, Scott.
Scott Giacobello - Aadi Bioscience, Inc. - Interim CEO, President & CFO
All right. So Roger, thank you for having me today. It's a pleasure to be here to talk to you about Aadi. Obviously, everyone's familiar with the forward-looking statements. So I'll move right into just a quick overall summary of Aadi.
Aadi is a commercial-stage precision oncology company focused on developing and commercializing genetically defined cancers with mTOR pathway alterations -- yeah, alterations in the mTOR pathway genes. We have a commercial product called FYARRO that was approved late in 2021, has been out on the market since February of last year. And it's for the treatment of an ultra-rare sarcoma known as advanced malignant PEComa.
We're very pleased with the launch progress. On our
Aadi Bioscience Inc at Jefferies Healthcare Conference Transcript
Feb 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers